AFT Pharmaceuticals Eyes Record Sales and Global Expansion

AFT Pharmaceuticals Ltd. ( (AU:AFP) ) just unveiled an announcement.

AFT Pharmaceuticals is poised for significant growth, with expectations of achieving record sales of over $200M in FY25, despite earlier sales disruptions. The company is strategically expanding its product pipeline and market presence across Australia, New Zealand, the USA, Canada, South Africa, Europe, and China. These strategic initiatives, including diversifying revenue streams and enhancing R&D, aim to bolster long-term shareholder returns, although they may impact short-term earnings. The introduction of new products like Combogesic IV and regulatory progress in new markets are pivotal to their international growth strategy.

More about AFT Pharmaceuticals Ltd.

AFT Pharmaceuticals Ltd., based in Auckland, New Zealand, operates within the pharmaceutical industry, developing and distributing a range of medicines. Their primary focus includes pain management products such as Combogesic and Maxigesic, which are marketed in various international markets including Australia, New Zealand, the USA, Canada, and regions in Europe and Asia.

YTD Price Performance: 0.0%

Average Trading Volume: 2,674

Technical Sentiment Consensus Rating: Buy

Current Market Cap: A$281M

See more insights into AFP stock on TipRanks’ Stock Analysis page.